Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir

HIV Medicine

Volumn 7, Issue 2, 2006, Pages 67-74

  Hill, A ^a   Walmsley, S ^b   Clotet, B ^c   Molto, J ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Drug resistance; Genotype; HIV; Phenotype; Protease inhibitors; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

CLINICAL TRIAL; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; GENE MUTATION; GENETIC ALGORITHM; GENETIC DATABASE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SITE DIRECTED MUTAGENESIS; VALIDATION STUDY; VIRUS RESISTANCE;

ALGORITHMS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PHENOTYPE; RITONAVIR; SAQUINAVIR;

EID: 33645975816     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00351.x     Document Type: Review

References (48)

1. Craig C, Duncan I, Hockley D, Grief C, Roberts N, Mills J. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16: 295-305.
2. Gieschke R, Fotteler B, Buss N, Steimer J. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive adults. Clin Pharmacokinet 1999; 37: 75-86.
3. Mitsuyasu R, Skolnik P, Cohen S et al. Activity of the soft gelatine formulation of saquinavir in combination therapy in antiretroviral naïve patients. AIDS 1998; 12: F103-F109.
4. Kilby JM, Sfakianos G, Gizzi N et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44: 2672-2678.
5. Veldkamp A, van Heeswijk R, Mulder J et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1 infected adults. J Acquir Immune Defic Syndr 2001; 27: 344-349.
6. Boffito M, Dickinson L, Hill A et al. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: Comparison with the standard twice-daily regimen. Antiviral Ther 2004; 9: 423-429.
7. Ford J, Boffito M, Wildfire A et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2388-2393.
8. Gisolf E, Jurriaans S, Pelgrom J et al. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. AIDS 2000; 14: 405 - 413.
9. Cameron D, Japour A, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1998; 13: 213-224.
10. Dragsted U, Gerstoft J, Pedersen C et al. Randomised trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1 infected patients: The MaxCmin 1 trial. J Infect Dis 2003; 188: 635-642.
11. Youle M, Gerstoft J, Fox Z et al. The final 48 week analysis of a phase IV, randomised, open-label, multicentre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg BID) versus saquinavir/ ritonavir (1000/100 mg BID): The MaxCmin 2 trial. 9th European AIDS Conference (EACS). Warsaw, Poland, October 2003 [Abstract F11/3].
12. Montaner J, Saag M, Barylski C, Siemon-Hryczyk P. Focus Study: saquinavir QD regimen versus efavirenz QD regimen week 48 analysis in HIV infected patients. 42nd International Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September 2002 [Abstract H-167].
13. Ananworanich J, Ruxrunghtham K, Siangphoe U et al. A prospective cohort study of efficacy and safety of 2 NRTIs plus once-daily ritonavir boosted saquinavir hard gel capsule (SQV-HGC/R) at 24 weeks. XV. International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract TuPeB4469].
14. Clotet B, Menedez-Arias L, Schapiro J et al. Guide to Management of HIV Drug Resistance, Antiretroviral Pharmacokinetics and Viral Hepatitis in HIV Infected Subjects, 4th edn. Barcelona, Fundació de Lluita contra la SIDA, 2004.
15. Sturmer M, Doerr H, Staszeswki S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antiviral Ther 2003; 8: 239-244.
16. Fox Z, Gerstoft J, Dragsted U et al. Comparison of 6 genotypic resistance algorithms for predicting viral load change to week 4. International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 2004, [Abstract H-185].
17. Roberts N, Craig C, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice. AIDS 1998; 12: 453-460.
18. Rose R, Gong Y, Greytock D et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996; 93: 1648-1653.
19. de la Carriere LC, Paulous S, Clavel F, Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999; 73: 3455-3459.
20. Sune C, Brennan L, Stover DR, Klimkait T. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. Clin Microbiol Infect 2004; 10: 119-126.
21. Johnson V, Brun-Vezinet F, Clotet B. Update of the drug resistance mutations in HIV-1: 2004. Topics HIV Med 2004; 12: 119-124.
22. Parkin N, Lie Y, Hellmann N et al. Letter. J Infect Dis 2000; 181: 1864-1865.
23. Parkin N, Chappey C and the Virologic Clinical Reference Laboratory. Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 and 90: Modulatory effects at secondary positions. 8th International HIV Resistance Workshop. Sitges, Spain, June 2000 [Abstract 152].
24. Tsai K, Heilik-Snyder G, Ravindran P et al. Changes in genotypic resistance patterns for saquinavir, lopinavir and amprenavir with rising phenotypic cut-off levels: Analysis of TORO database. 13th International HIV Resistance Workshop. Santa Cruz, Tenerife, Spain, June 2003 [Abstract 113].
25. Colonno R, Friborg J, Rose R, Lam E, Parkin N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir containing regimens. 10th International HIV Resistance Workshop. Seville, Spain, June 2002 [Abstract 004].
26. Maguire M, Shortino D, Klein A et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1 infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadminstered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46: 731-738.
27. Martinez-Picado J, Savara A, Shi L et al. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275: 318-322.
28. Hertogs K, Bloor S, Kemp S et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2000; 14: 1203-1210.
29. Casado JL, Moreno A, Sabido R. Individualizing salvage regimens: The inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003; 17: 262-264.
30. Squires K, McCallister S, Lazzarin A et al. Tipranavir/ritonavir (TPV/;r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: Correlation of baseline genotype and antiviral activity in BI 1182.52. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 2003 [Abstract 612].
31. Peeters M, Van Baelen B, De Meyer S et al. TMC114/RTV activity in multiple PI-experienced patients: Correlation of baseline genotype, phenotype, PK and IQ with antiviral activity at day 14. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 533].
32. Hazen R, St Clair M, Hanlon M et al. GW0385, a broad spectrum, ultrapotent inhibitor of wild-type and protease inhibitor-resistant HIV-1. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 2004 [Abstract 541].
33. Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24 week data. 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 2004 [Abstract 114].
34. Hill A, Telenti A. Standardisation of resistance cut-off levels. 2004, in press.
35. Loutfy MR, Raboud JM, Walmsley SL et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antiviral Ther 2004; 9: 595-602.
36. Valer L, de Mendosa C, Gonzalez de Requena D et al. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002; 16: 1964-1966.
37. Marcelin AG, Dalban C, Peytavin G et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004; 48: 4687-4692.
38. Barreiro P, Camino N, de Mendoza C et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002; 20: 438-443.
39. Morand-Joubert L, Lacombe K, Duguit C et al. Impact of genotypic resistance in protease inhibitor experienced patients treated by a combination including saquinavir and ritonavir. XV. International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract 5722].
40. Perez-Elias M, Garcia-Arota I, Muñoz V et al. Phenotype or virtual phenotype for choosing antiretroviral therapy alter failure: A prospective, randomised study. Antiviral Ther 2003; 8: 577-584.
41. Bachelor L, Winters B, Nauwelaers D et al. Estimation of phenotypic clinical cutoffs for Virtual Phenotype through meta-analysis of clinical trial and cohort data. 12th International HIV Resistance Workshop. Santa Cruz, Tenerife, Spain, June 2004 [Abstract 138].
42. Piketty C, Race E, Castiel P et al. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five drug combination including ritonavir, saquinavir and efvirenz. AIDS 2000; 14: 626-628.
43. Meynard J, Vray M, Morand-Joubert M et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002; 16: 727-736.
44. Valer L, Hill A, Gonzalez de Requena D et al. Predictive power of single mutations, mutation score and Cmin levels for response to salvage regimens including saquinavir/r 1000/100 mg BID. 10th International HIV Resistance Workshop. Seville, Spain, June 2002 [Abstract 98].
45. Meyers DL, Leith J, Valdez H et al. Impact of 3 or 4 protease mutations at codons 33, 82, 84 and 90 on 2-week virologic responses to tipranavir, lopinavir, amprenavir and saquinavir, all boosted by ritonavir in Phase IIb Trial BI 1182.51. XIII. International HIV Resistance Workshop, Tenerife, June 2004 [Abstract 129]. 2004; 9: S143.
46. Ledergerber B, Lundgren J, Walker A et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62.
47. Gianotti N, Soria A, Galli L et al. Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor resistant HIV-infected patients: 24 week immunological outcome. AIDS 2004; 18: 8.
48. Molla A, Mo H, Vasavanonda S et al. In vitro interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002; 46: 2249-2253.